The use of glucagon-like peptide-1 (GLP-1) agonists has surged, revitalizing various sectors within life sciences, particularly in aesthetics. With a global prescription growth of approximately 38% annually from 2022 to 2024, this class of medications is anticipated to achieve sales of $100 billion by 2030. Their influence extends well beyond cardiometabolic benefits; they are redefining patient appearances and, in turn, propelling the demand for aesthetic treatments.

Survey Insights: A New Patient Demographic

To assess the effects of GLP-1-induced weight loss on the aesthetics sector, we conducted a survey involving 174 medical spas, dermatology clinics, and plastic surgery centers at the end of 2024. Our findings highlight a notable shift in consumer behavior, illustrating that 63% of patients seeking aesthetic procedures were newcomers to medical aesthetics. Half of these individuals had never contemplated aesthetic treatments prior to their weight loss journey.

Understanding GLP-1 Patients’ Needs

As the patient base diversifies, recognizing the unique demands of GLP-1 patients becomes crucial for the aesthetic industry. Below are several characteristics defining this emerging cohort:

• Multiple Aesthetic Concerns: Patients often experience a range of issues stemming from weight loss, including skin laxity and volume loss. Feedback indicates that 61% of individuals who sought treatment lost between 11% and 30% of their body weight.
• Diverse Aesthetic Goals: Approximately 56% of GLP-1 patients aspire to achieve a more natural look, reminiscent of their pre-weight-loss appearance, while 44% are open to exploring innovative aesthetics.
• Combination Therapies: Aesthetic providers recognize the complexity of treating GLP-1 patients and see potential in combination treatments. Nearly a third believe further advancements are necessary for improved outcomes.
• Financial Implications: Patients are encountering mixed financial scenarios; while 60% noted a decrease in overall spending on aesthetics, 40% opted for increased investment due to heightened self-awareness post-weight loss.

Strategic Recommendations for Aesthetic Providers

To effectively cater to the needs of GLP-1 patients, stakeholders in the aesthetic industry can take several targeted actions:

1. Revamp Marketing Strategies: Tailored marketing initiatives should focus on the unique demographic and psychographic profiles of GLP-1 patients, utilizing digital platforms for educational outreach.
2. Implement Tiered Pricing Models: Providers can enhance accessibility through flexible pricing structures that cater to diverse financial capabilities, including plans for routine maintenance and comprehensive treatment packages.
3. Develop Customized Treatment Protocols: Collaborations with manufacturers can lead to the creation of algorithms specifically designed for post-weight-loss patients, optimizing treatment timing and effectiveness.
4. Broaden Access to Combination Therapies: It’s essential to integrate novel technologies and combination therapies that align with the multifaceted needs of GLP-1 patients.
5. Pursue Strategic Investments: The burgeoning demand for integrated treatment solutions opens doors for significant investment opportunities, encouraging mergers and acquisitions within the aesthetic landscape.